We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Nautilus Biotechnology Inc (NAUT) USD0.0001

Sell:$2.93 Buy:$2.97 Change: $0.18 (6.50%)
NASDAQ:0.12%
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
Sell:$2.93
Buy:$2.97
Change: $0.18 (6.50%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
Sell:$2.93
Buy:$2.97
Change: $0.18 (6.50%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.

Contact details

Address:
2701 Eastlake Ave East
SEATTLE
98102
United States
Telephone:
+1 (206) 3332001
Website:
https://www.nautilus.bio/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
NAUT
ISIN:
US63909J1088
Market cap:
$346.52 million
Shares in issue:
125.10 million
Sector:
Life Sciences Tools & Services
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Sujal Patel
    President, Chief Executive Officer, Secretary, Director
  • Anna Mowry
    Chief Financial Officer, Treasurer
  • Gwen Weld
    Chief People Officer
  • Mary Godwin
    Senior Vice President - Operations
  • Nick Nelson
    Chief Business Officer, Senior Vice President - Business Development
  • Subramanian Sankar
    Senior Vice President - Product Development
  • Parag Mallick
    Chief Scientist, Director
  • Matthew Murphy
    General Counsel

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.